Vascular Endothelial Expression of Indoleamine 2,3-Dioxygenase 1 Forms a Positive Gradient towards the Feto-Maternal Interface by Blaschitz, Astrid et al.
Vascular Endothelial Expression of Indoleamine 2,3-
Dioxygenase 1 Forms a Positive Gradient towards the
Feto-Maternal Interface
Astrid Blaschitz
1, Martin Gauster
1, Dietmar Fuchs
2, Ingrid Lang
1, Petra Maschke
1, Daniela Ulrich
3, Eva
Karpf
4, Osamu Takikawa
5, Michael G. Schimek
6, Gottfried Dohr
1, Peter Sedlmayr
1*
1Institute of Cell Biology, Histology and Embryology, Center for Molecular Medicine, Medical University of Graz, Graz, Austria, 2Division of Biological Chemistry, Biocenter,
Innsbruck Medical University, Innsbruck, Austria, 3Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria, 4Institute of Pathology, Center for
Applied Biomedicine, Medical University of Graz, Graz, Austria, 5Laboratory of Radiation Safety, National Institute of Longevity Science, National Center for Geriatrics and
Gerontology, Obu City, Japan, 6Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
Abstract
We describe the distribution of indoleamine 2,3-dioxygenase 1 (IDO1) in vascular endothelium of human first-trimester and
term placenta. Expression of IDO1 protein on the fetal side of the interface extended from almost exclusively sub-
trophoblastic capillaries in first-trimester placenta to a nearly general presence on villous vascular endothelia at term,
including also most bigger vessels such as villous arteries and veins of stem villi and vessels of the chorionic plate. Umbilical
cord vessels were generally negative for IDO1 protein. In the fetal part of the placenta positivity for IDO1 was restricted to
vascular endothelium, which did not co-express HLA-DR. This finding paralleled detectability of IDO1 mRNA in first trimester
and term tissue and a high increase in the kynurenine to tryptophan ratio in chorionic villous tissue from first trimester to
term placenta. Endothelial cells isolated from the chorionic plate of term placenta expressed IDO1 mRNA in contrast to
endothelial cells originating from human umbilical vein, iliac vein or aorta. In first trimester decidua we found endothelium
of arteries rather than veins expressing IDO1, which was complementory to expression of HLA-DR. An estimation of IDO
activity on the basis of the ratio of kynurenine and tryptophan in blood taken from vessels of the chorionic plate of term
placenta indicated far higher values than those found in the peripheral blood of adults. Thus, a gradient of vascular
endothelial IDO1 expression is present at both sides of the feto-maternal interface.
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Introduction
Pregnancy implicates a state of peaceful coexistence between
hemiallogeneic tissues of the mother and the fetus. Interest in the
role of the tryptophan-degrading enzyme indoleamine 2,3-
dioxygenase in the context of feto-maternal tolerance and in
immunosuppression in general was aroused more than ten years
ago [1,2]. While placental expression of indoleamine 2,3-
dioxygenase (IDO) may not necessarily be a prerequisite for the
tolerance-mediating role of the enzyme, most studies have focused
on investigations of the direct cellular interfaces between mother
and fetus, which is located in the decidua basalis, where the fetally
derived invading trophoblast may be recognized and tolerated by
the maternal uterine immune system [3] and the huge surface of
syncytiotrophoblast which covers the placental villous trees and
separates the maternal and fetal blood circulations from each
other. So a number of efforts have been undertaken for
localization of the enzyme in the placenta. Initially IDO
expression at the feto-maternal interface was described in
glandular epithelial cells of uterine glands, trophoblast cells and
macrophages [4,5,6,7], but also endothelial cells might express
IDO [6,7] however, not all of the studies came to the same
immunolocalization results. IDO expression in dendritic cells of
tumor-draining lymph nodes [8] prompted an unsuccessful search
for the same phenomenon in the regional lymph nodes of uteri of
pregnant mice (P. Arck, A. Blaschitz, P. Sedlmayr; unpublished
observations). Other than mediating immunosuppression, IDO
displays antimicrobial and antiviral effects by reducing the
availability of the essential amino acid tryptophan in the
inflammatory environment [9,10].
Further enzymes catalyzing the same step in tryptophan
catabolizm may also be expressed in the placenta. This has been
shown for tryptophan-dioxygenase (TDO) in the mouse, where
expression of TDO precedes expression of IDO [11]. TDO
displays low sequence similarity to IDO and in contrast to IDO is
not blocked by 1-methyl tryptophan [12]. Recently indoleamine
2,3-dioxygenase 2 (IDO2) with 43% identity at amino acid level to
IDO (henceforth named IDO1) has been characterized. It is also
expressed in the placenta and is preferentially inhibited by 1-
methyl-D-tryptophan, in contrast to preferential inhibition of
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21774IDO1 by the L-enantiomer. The tryptophan-degrading activity of
IDO2 is probably much lower compared to IDO1, the biological
role as yet unclear [13,14,15,16,17].
Vascular endothelial cells (EC) have been implicated in
expression of IDO1 and tryptophan-degrading activity in the
context of infectious diseases, tumour pathology and transplanta-
tion [18]. Taking into account the particular immunological
situation of the utero-placental unit, it was of special interest to
investigate IDO1 expression and activity with special regard to
vascular endothelial cells on both sides of the feto-maternal
interface.
In the present study we investigated paraffin-embedded
placenta and decidua tissues from early and term gestational
stages and various anatomical locations using an improved
immunohistochemical protocol. Furthermore we measured the
enzyme activities of sera and tissues and identified IDO1 mRNA
in isolated endothelial cells from the placenta and other organs.
Materials and Methods
Ethics Statement
The present study was approved by the Ethics Committee of the
Medical University of Graz, Austria (No. 20-074 ex 08/09 and
No. 19-293 ex 07/08). The Ethics Committee of the Medical
University of Graz (Ethikkommission der Medizinischen Uni-
versita ¨t Graz, http://www.meduni-graz.at/ethikkommission/
Graz/) is registered at the Office for Human Research Protections
(OHRP) of the US Department of Health and Human Services
(DHHS) with the number IRB00002556. Written informed
consent was obtained from the blood and tissue donors involved
in the study. In addition, samples taken from the paraffin block
archive of the Institute of Cell Biology, Histology and Embryology
in Graz were used. Use of these archival samples was approved by
the Ethics Committee of the Medical University of Graz as of
March 19, 1999 and September 11, 2003, without the condition of
obtaining written consent.
Tissues and cells
Tissue and blood samples from 10 normal term placentas were
collected after spontaneous delivery or caesarian section and 10
samples from first trimester pregnancy were obtained after
pregnancy terminations between the 6
th and the 11
th week.
Furthermore, the following archival samples of interest for this
study were used: three samples of hysterectomy post partum (one
due to placenta increta, two due to postpartal atony), a sample of a
uterus in the 22
nd week of pregnancy from a case of uterine
rupture and a sample of abdominal skin of a pregnant woman had
been excised for a scar from a previous caesarian section during
Figure 1. Immunohistochemical staining of first trimester placenta serial paraffin sections at the 11
th week of pregnancy. Villous
chorion (A, B) and umbilical cord vessels (C, D) stained for IDO1 (A, C) and for the endothelial marker CD34 (B, D); bigger vessels located more to the
center of the villi are indicated by arrowheads, capillaries forming a network beneath the trophoblastic double layer stain positive for IDO1. The scale
bar represents 100 mm.
doi:10.1371/journal.pone.0021774.g001
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th week). For the purpose of
comparison of concentrations of tryptophan and kynurenine we
used a set of data established previously from the peripheral blood
of 38 healthy blood donors [19].
Placental endothelial cells (PEC) were isolated from placental
tissue as described previously [20]. Endothelial cells from isolated
V. iliacae originating from adult donors were harvested by
enzymatic digestion of the inner surface of the blood vessel with
Dulbeccos modified minimal essential medium (DMEM; PAA)
containing 200 U/ml collagenase (type II; Sigma, Taufkirchen,
Germany), trypsin inhibitor (type II S; 1 mg/ml; Sigma), calcium
chloride (0.5 m; Roth), essential and non-essential amino acids
(0.02 v/v; PAA), vitamins (0.01 v/v; PAA), bovine serum albumin
(BSA; 2 mg/ml; Sigma), 5% fetal calf serum (FCS; PAA) and
antibiotics. Digestion was allowed to proceed at 37uC for 60 min
before flushing the collagenase solution containing the endothelial
cells. The cell suspension was collected in FCS and centrifuged at
200 x g for 5 min. The pellet thus obtained was resuspended in
EGM-MV medium (Lonza, Verviers, Belgium) and the cells were
plated on culture plates pre-coated with 1% gelatin (Sigma). The
endothelial identity of the isolated cells was confirmed by staining
for the classical endothelial marker von Willebrand factor and by
measuring of DiI-Ac-LDL uptake. In general, $99% cells in the
primary culture expressed these endothelial cell characteristics.
Human umbilical vein endothelial cells (HUVEC) were purchased
from PromoCell (Heidelberg, Germany) and human aortic
endothelial cells (HAEC) were obtained from Lonza. All
endothelial cell types were cultured in EGM-MV medium (Lonza)
including the supplement kit EGM-MV SingleQuots (Lonza) in
humidified atmosphere containing 5% CO2 at 37uC.
Antibodies
We used a mouse monoclonal anti-IDO1 antibody (IgG1) at a
final concentration of 1 mg/ml [21]. For identifying extra-villous
trophoblasts we utilized an antibody against HLA-G (BD Pharmin-
gen, clone 4H84, mouse IgG1, 1 mg/ml) [22,23]. An antibody
against the epitope class II of CD34 (Dako, clone QBEnd10, mouse
IgG, 0.05 mg/ml) was employed for staining endothelial cells in
serial sections. Anti-HLA-DR was obtained from Becton-Dickinson
(Schwechat, Austria) and used at a dilution of 1:50. Anti-CD163
(IgG1, clone 5C6-FAT, Acris, Hiddenhausen, Germany) was
applied as a macrophage marker. For negative controls we used
an IgG1 isotype control antibody (Dako) at 1 mg/ml.
Immunohistochemistry
For immunolocalisation only paraffin sections were used. Tissues
were fixed between 24 h and 3 d in 4% buffered formalin at room
temperature and embedded in paraffin following a standard over-
night dehydration and paraffin infiltration protocol. For staining of
some serial sections with anti-HLA-DR and anti-IDO1 we used
HOPE-fixed paraffin sections [24]. 5 mm thick sections were cut on
a sledge microtome and dried on a 50uC hot plate over night.
Sections were labelled with the anti-IDO antibody following
heat induced antigen retrieval with at pH 9 (Epitope Retrieval
Solution pH 9, Eubio, Vienna, Austria). This was done following
optimization of the retrieval protocol where we labelled in
comparison some slides after pre-treatment with citrate buffer at
pH 6 or without any pretreatment. Before staining the slides were
Figure 2. Immunohistochemical staining of serial paraffin
sections of first trimester decidua basalis (D) showing also
partly villous tissue (V). The sections are stained for IDO1 (A), the
endothelial marker CD34 (B) and HLA–G, a marker for extravillous
trophoblast (C). Arrow heads heads point towards the epithelium of
uterine glands, some endothelia are indicated by arrows. The scale bar
represents 100 mm.
doi:10.1371/journal.pone.0021774.g002
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let cool down for 20 min and washed in distilled water. The
detection protocol started with a 12 min step of blocking
endogenous peroxidase (Hydrogen Peroxide Block, LabVision,
Fremont, CA) followed by a 7 min protein block (included in the
Ultravision LP Detection system) and a 45 min step of primary
antibody incubation. Bound antibodies were detected using a
polyvalent (mouse, rabbit) horseradish-peroxidase polymer system
(Ultravision LP Detection system, LabVision, Fremont, CA) and a
10 minute amino-ethyl-carbazole (AEC) incubation step. All slides
were counter-stained with Mayer’s hemalum. Washing steps were
done using TBS/0.05%Tween 20. For HLA-DR labelling of
HOPE sections the antigen retrieval step was not necessary and
therefore skipped.
Measurement of tryptophan and kynurenine
9 different samples of umbilical cord blood were collected
shortly after delivery, sera were separated from blood cells after
clotting and frozen until examination.
For collection of sera from chorionic plate arteries and veins the
umbilical cord vessels were clamped and the placentae were
placed directly on ice. The amnion was removed and a cannula
was inserted into a chorionic artery directed to the umbilical artery
to collect the arterial blood. Another cannula was introduced into
a chorionic vein in the direction of the umbilical vein to harvest
venous blood. As endothelium of both arteries and veins were
found to express IDO1, these samples were combined into one
group for statistical analysis.
In some instances plasma was used instead of sera. Earlier
studies had shown no differences for the analysis of tryptophan
and kynurenine between serum and plasma (D. Fuchs, unpub-
lished results).
Chorionic villous tissues from term and first trimester placentas
were balanced and frozen. Tissue material was suspended in 0.5 ml
5 mM DTE (7.71 mg/10 ml), immediately vortex mixed and then
kept on a shaker for 15 min. The resulting suspension was
centrifuged for 10 min at room temperature at 13,000 x g.F o rt h e
determination of kynurenine and tryptophan concentrations HPLC
with the internal calibrator 3-nitro-L-tyrosine was applied [25]. To
precipitate protein 100 ml culture supernatants or serum specimens
were treated with 50 mL 2 mol/L trichloroacetic acid and
centrifuged. Chromatography was performed on reversed-phase
cartridges LiChroCART RP18 columns, tryptophan was monitored
via its fluorescence at 285 nm excitation and 365 nm emission
wavelengths, kynurenine was measured by its UV absorption at
360 nm wavelength. The kynurenine to tryptophan ratio (kyn/trp)
was calculated and expressed as mmol kynurenine/mmol trypto-
phan, kyn/trp allowing an estimate of IDO activity [25].
RNA isolation of placental tissue and endothelial cells
Total RNA from placental tissues and endothelial cells was
isolated with Tri Reagent (Molecular Research Center, Cincin-
nati, OH, USA) according to the manufacturer’s instructions. In
brief, small slices of frozen placenta tissue (200 mg) were
homogenized in 1 ml Tri Reagent before further processing.
RNA from endothelial cells was isolated by directly lysing the cells
with Tri Reagent in the culture dishes.
Semiquantitative RT-PCR
For semi-quantitative RT-PCR a commercially available RT-
PCR Kit (OneStep RT-PCR Kit, Qiagen, Hilden, Germany) was
used according to the manufacturer’s manual. Each RT-PCR
reaction contained 100 ng total RNA from tissue or primary cells.
Primers were designed to get PCR products spanning exon-exon
boundaries of mRNAs and had the following sequences: b-actin
(GACTACCTCATGAAGATC and GATCCACATCTGCTG-
GAA; product 513 bp) and IDO (GGCACACGCTATGGAA-
AACT and CGGACATCTCCATGACCTTT; product 297 bp).
The RT-PCR program included an initial 30 min step at 50uC for
reverse transcription and a second 15 min step at 95uC to activate
DNA polymerase. The following amplification was performed by a
3-step cycling (30 sec at 94uC, 30 sec at 60uC and 1 min at 72uC)
using 24 cycles for b-actin and 32 cycles for IDO1. The PCR
products were separated on 1.5% (w/v) agarose gels (SeaKem LE
Agarose, Cambrex) and were documented using the FluorChemQ
(Alpha Innotech) documentation system.
Statistics
The statistical analysis of differences in concentrations in three
blood compartments was performed with StatXact (a statistical
package for exact nonparametric inference, part of the Cytel
Studio 9 software). Mean rank differences were tested against a
two-sided alternative with the Wilcoxon-Mann-Whitney-test. Each
Figure 3. Comparison of localization of IDO1 (A) and HLA-DR (B) in first trimester decidua. Serial paraffin sections are stained by
immunohistochemistry. Designated are uterine glands (asterisks), the endothelium of spiral arteries (open arrowhead) and of veins (arrow). Please
note that apart from expression in the endothelium of veins, HLA-DR is expressed by macrophages. Scale bar=100 mm.
doi:10.1371/journal.pone.0021774.g003
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was separately compared across the three compartiments (com-
prising independent samples). Applying Kruskal-Wallis, we tested
against an unordered alternative (there is no evidence for a certain
ordering of the compartiments) under the distributional assump-
tion that the samples have the same shape but their medians are
shifted with respect to each other. Because of the small sample
sizes of two compartiments, in addition to the usual asymptotic
result we calculated the exact result of the comparisons.
Results
Localization of IDO1 protein
First trimester placenta. In villous chorion of tissue samples
collected between the 6
th and the 11
th week of gestation expression of
IDO1 was in most cases restricted to capillaries immediately below
the trophoblastic layer (Fig.1a). Bigger vessels in the inner
mesenchymal core, located at more distance from the maternal
blood, were negative for IDO1, which was also absent from umbilical
cord vessels (Fig. 1c). Trophoblast cells were generally negative.
Expression of IDO1 in decidua basalis was found in glandular
epithelial cells as well as in vascular endothelial cells (Fig. 2a).
Invasive HLA-G positive extravillous trophoblasts (Fig. 2c) did not
stain for IDO1 in the tissue samples of decidua tested. Endothelial
expression of IDO1 did not co-localize with HLA-DR, as studied
in four tissue samples: Whereas IDO1 was detected predominantly
in arteries, HLA-DR was found mainly in veins (Fig. 3a, b).
Term placenta. At term,theintensityofimmunohistochemical
staining was found markedly increased in comparison to first
trimester villi. Most endothelia of the fetal blood vessels are stained
intensely for IDO1 (Fig. 4a), including also bigger vessels such as
arteries and veins of stem villi. Trophoblast cells were generally
negative. In the basal plate we identified cells lining the intervillous
space as being endothelial cells (Fig. 4b); this layer expressed IDO1
as demonstrated in serial sections (Fig. 4). The extravillous
trophoblast in term basal plate was found negative (Fig. 4). In
contrast to IDO1 expression, HLA-DR was absent from vascular
endothelium of small as well as of bigger vessels of chorionic villi and
presentonHofbauercellsonly,asfoundinfivetissuesamples(Fig.5).
Bigger vessels in the chorionic plate stained moderately for IDO1
(Fig. 6a) in most but not all of the placenta tissue samples studied.
None of the ten placentas tested expressed IDO1 in vascular
endothelia of the umbilical cord (Fig. 6c).
Investigation of archival tissue paraffin blocks from a 22
nd week
pregnancy, containing decidua and the whole uterine wall,
revealed decreasing intensity of endothelial IDO1 staining towards
the outer myometrium (Fig. 7). Similar results were obtained by
analyzing uterine tissues post partum from three patients. One
sample of a uterine artery and one of abdominal skin of a pregnant
woman did not stain for IDO1 either (data not shown), indicating
that maternal vessel endothelia located at a distance to the feto-
maternal interface do not express IDO1.
Expression of IDO1 mRNA in placenta tissues and
isolated endothelial cells
The results of RT-PCR from placenta tissues indicated a
marked increase in mRNA for IDO1 from first trimester to term
(Fig. 8). In addition, we analyzed freshly isolated endothelia from
chorionic plate veins and arteries. We compared the results to
other types of endothelial cells such as the human umblical cord
Figure 4. Immunohistochemical staining of term placenta serial
sections including the basal plate. IDO1 labelling results in staining
of vascular endothelium, leaving villous and extravillous trophoblast
unstained (A). The anti-CD34 antibody stains endothelial cells of the
fetal circulation in the villous mesenchymal core and also endothelial
cells which line the intervillous space; the arrowhead indicates a special
site where endothelium connects with syncytiotrophoblast (B). HLA-G
identifies extravillous cytotrophoblasts located in the basal plate (C).
Scale bar represents 100 mm.
doi:10.1371/journal.pone.0021774.g004
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iliaca of the human aorta. IDO1 was detected in freshly isolated
endothelial cells from the chorionic plate, whereas the other
endothelia were negative (Fig. 8).
Chorionic tryptophan degrading activity
We confirmed the upregulation of IDO1 from first trimester to
termplacentabymeasuringthelevelsoftryptophanand kynurenine
and the Kyn/trp ratio in lysed tissues (Fig. 9a–c). In parallel to our
Figure 5. Immunohistochemical staining of paraffin sections of term villous tissue. Expression of HLA-DR (A) is allocated to Hofbauer cells,
as demonstrated in a serial section stained for the macrophage marker CD163 (B), open arrowheads indicate vascular endothelia. Scale bars=50 mm.
doi:10.1371/journal.pone.0021774.g005
Figure 6. Immunohistochemical staining of serial paraffin sections of term placenta chorionic plate (A, B) and umbilical cord (C, D).
The sections are stained for IDO1 (A, C) and the endothelial cell marker CD34 (B, D).Scale bar represents 100 mm.
doi:10.1371/journal.pone.0021774.g006
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tration measured in the tissue decreased (p,0.001) from first
trimester villi (57.4+31.13 mmol/mg, mean+standard deviation) to
term villi (7.2+8.14 mmol/mg, Fig. 9a), the concentration of
kynurenine increased (p,0.001) from first trimester (5.3+
8.94 mmol/mg) to term villi (38.0+11.97 mmol/mg, Fig. 9b). So
the mean kynurenine/tryptophan ratio, allowing for an estimation
of antecedent IDO activity of placental tissue increases about
thousand-fold (p,0.001) from first trimester (0.076+0.072) to term
placenta (74.419+126.291) (Fig. 9c).
As endothelial IDO1 may be supposed to act upon the vessel
content and differencesinconcentrationsoftryptophandegradation
products might be expected after delivery, i. e. after interruption of
the blood circulation, we tested for the concentrations of tryptophan
and kynurenine in various blood compartments (Fig. 9d–f).
Concentrations of tryptophan were 80.2 mmol/L (median, range
52.9–93.8)inblooddrawnfromvesselsofthe chorionicplate(n=8),
67.0 (62.4–78.4) mmol/L for umbilical cord blood (n=9), and 57.7
(43.6–75.1) mmol/L for peripheral blood from adult persons
(n=38). We detected kynurenine at 5.9 mmol/L (median, range
4.3–8.5) in blood from vessels of the chorionic plate, at 4.7 (4.0–
6.4) mmol/L in umbilical cord blood and at 1.4 (0.7–2.3) mmol/L in
peripheral blood. The kynurenine/tryptophan ratio was 0.068
(median, range 0.0601–0.106) for blood from vessels of the
chorionic plate, 0.0707 (0.0595–0.0995) for umbilical cord blood,
and 0.0238 (median, range 0.0131–0.0384) for peripheral blood.
Assuming a significance level of 0.01, the test results for all three
parameters are significant. The exact results fully support the
obtained asymptotic two-sided p-values from the Kruskal-Wallis
tests. Thus, the null hypothesis of identical sample medians can be
rejected throughout.
In order to avoid the problem of multiple testing, we confined
the subsequent analysis to comparison of blood from the chorionic
vessels to peripheral blood, resulting in significant mean rank
differences for all three parameters (tryptophan, kynurenine and
the kynurenine/tryptophan ratio) at the level of p,0.001.
Discussion
In extension of our previous observation of expression of IDO1
in the vascular endothelium of the decidua and the chorionic villi
[7], we here report findings regarding the distribution of
expression of IDO1 in the vasculature of the placenta. We found
expression of IDO1 in endothelial cells of the villous chorion and
chorionic tryptophan degrading activity increase during the course
of pregnancy. For both fetal and maternal vascular systems we
show an gradient of endothelial IDO1 expression towards to the
feto-maternal contact zone in the human placenta (Fig. 10).
Furthermore, in parallel with the stage of gestation this expression
extends to locations increasingly distant from the interface (which
is the case for the fetal side to a higher degree than for the
maternal one). We see this phenomenon in context with the
concentration of kynurenine measured in chorionic villous tissue,
which increases with the stage of gestation, and also with the
difference in the kyn/trp ratio in blood taken from the chorionic
plate after delivery in contrast to adult blood.
There is considerable discrepancy among published reports on
IDO1 expression in the human placenta. Causes accounting for
this may include the variety of antibodies, concentrations and
detection systems which have been used. The antigen or epitope
retrieval may also affect the results. In Fig. 11 we show the impact
of modification of just the single parameter of antigen retrieval on
the outcome of immunohistological staining for IDO1 (compar-
ison of the results obtained on formalin-fixed paraffin sections after
heat induced epitope retrieval (HIER) with buffers at pH 6 and
pH 9 and without any antigen retrieval). We obtained best results
using HIER at pH 9; this was also shown for many other
antibodies [26].
In contrast to some earlier reports including ours, we find IDO1
neither in villous nor in extravillous trophoblast [4,5,6,7]. Earlier,
Figure 7. Paraffin sections of a uterine wall including the decidua in the 22
nd week of gestation, stained with anti-IDO1 antibody.
The trophoblast-invaded implantation site shows strong staining of vascular endothelial cells (A). In the second quarter of the uterine wall most of the
myometrial blood vessels are also labeled (B). The third quarter shows only one vessel stained (C) and in the outermost quarter of the uterus (D) none
of the vessels stain for IDO1. Scale bar represents 200 mm.
doi:10.1371/journal.pone.0021774.g007
Figure 8. Expression of IDO1 mRNA. Semi-quantitative RT-PCR
comparing IDO1 mRNA expression in first trimester and term placenta
tissues with endothelial cells isolated from term placenta chorionic
plate (PEC), a human umbilical vein endothelial cell line (HUVEC),
endothelial cells isolated from the iliac vein (V. iliaca) and a cell line from
human aortic endothelium (HAEC). The expression of beta-actin was
used as internal reference and water instead of total RNA served as non
template control (NTC).
doi:10.1371/journal.pone.0021774.g008
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)Avidin-Biotin- (LSAB) technique [7]. In combination with a far
more sensitive polymer-based detection system, the present report
is based on paraffin sections allowing for better immunolocaliza-
tion due to elimination of antigen carry-over. We argue that
further descriptions of IDO1 expression by the trophoblast may be
Figure 9. Chorionic tryptophan-degrading activity. Concentration of tryptophan (A, D), kynurenine (B, E) and the kyn/trp ratio (C, F) in placenta
villous tissues (A, B, C) at first trimester (grey bars) and at term (black bars; indicated are the means+SD. For all three comparisons p,0.001) and in
blood samples (D, E, F) from chorionic plate vessels of term placenta (CP, white bars), from umbilical cord blood (UC, light grey bars) and from
peripheral blood of healthy blood donors (PB, dark grey bars). D–F: Indicated are the medians and the ranges. Assuming a significance level of 0.01,
the test results for all three parameters are significant. The difference between the groups CP and PB is significant for all three parameters at p,0.001.
doi:10.1371/journal.pone.0021774.g009
Figure 10. Illustration of the IDO1 expression gradient in vascular endothelial cells of fetal and maternal blood circulations at the
utero-placental materno-fetal interface. The expression intensity increases close to the semi-allogeneic contact zone.
doi:10.1371/journal.pone.0021774.g010
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phosphatase [5], as placenta-specific endogenous alkaline phos-
phatase cannot be quenched sufficiently, and that IDO1-positive
EC which underlie the trophoblast layer closely may have
contaminated isolated trophoblasts in a study finding IDO1
mRNA in these cells [27]. A reported preferential staining of the
invasive extravillous cytotrophoblast may be based on non-specific
binding effects of an antibody to cryosections fixed with
combination of methanol and formalin, or to using the same
marker enzyme twice for immunohistochemical double-staining
[4]. Immunohistological evidence provided by Ligam et al. does
not allow for the conclusion of a localization of IDO1 to Hofbauer
cells [6]. Expression of IDO1 by CD14-positive cells in the
decidua could be ruled out in an earlier study [28]. Jones et al.
characterized CD34-negative mesenchymal stem cells isolated
from the human placenta which suppress allogeneic T cell
proliferation [29]. Our immunohistology showed chorionic cells
expressing IDO1 exclusively co-localizing with CD34. However,
we cannot exclude that CD34-negative cells isolated from the
placenta be induced in culture to express IDO1.
Our data leave us to conclude that tryptophan-degrading
activity in villous tissue (which increases massively from first
trimester to term in parallel to the vascular IDO1 expression) is
exclusively due to vascular endothelial expression of IDO1.
Vascular endothelial cells in chorionic villi do not co-express
MHC class II. This finding corresponds to a report of constitutive
IDO expression in the epididymis and the placenta in both
C57Bl/6 wild-type and IFN-gamma
2/2 mice, suggesting a
distinct regulatory mechanism for IDO1 induction in contrast to
the well-known up-regulation by IFN-gamma [30]. On the other
hand, we do see expression of HLA-DR in vessels of the decidua,
but this is mainly confined to the endothelium of veins, whereas
IDO1 expression in decidual endothelium is generally restricted to
arteries. Thus, it seems unlikely that IDO1 expression at this
location is related to secretion of IFN-gamma by the dense
population of decidua NK cells.
What may be the biological role of vascular endothelial IDO1 in
the vicinity of the feto-maternal interface?
It is reported that IDO-activity in cytokine-stimulated HUVECs
(but less so endothelial cells of other origin such as the saphenous
vein or internal mammary or radial arteries) suppresses allogeneic
T-cell responses. Transfection of HUVECs with IDO1 induces
anergy in allospecific T-cells which can also act as regulatory cells
[31]. In allotransplants tolerance was mediated by regulatory T
cell and IFN-gamma inducing the expression of IDO1 in EC of
the graft [32].
We may assume that the feto-maternal border, the villous
trophoblast layer, is not always perfectly impervious. This is clearly
not the case in the course of an intervention such as a chorionic
villous biopsy, but may also happen to some extent in a normal
pregancy, e. g. due to intense active movement of the fetus or
passive trauma from outside. In these cases an exchange of a small
amount of fetal and maternal blood is possible, which means that
immunocompetent lymphocytes come into contact with the
endothelium of the other organism. For both hemiallogeneic
organisms, suppression of an allogeneic immune response will be
mandatory in these cases. It is established that the fetal immune
system has the ability to respond to antigens as early as by 18
weeks of gestation [33]. A limited transfer of cells from the mother
to the fetus and vice versa is the basis for the well recognized
phenomenon of microchimerism [34,35]. Fetal Y-chromosome
DNA was detected in the maternal circulation in cellular
compartments beginning at 7 to 16 weeks [36,37]. On the other
hand, while blood exchange peaks at the perinatal stage, prenatal
Figure 11. Influence of heat induced epitope retrieval (HIER) on
IDO1 staining of formalin-fixed paraffin-embedded term
placenta sections. Staining without any pre-treatment (A) does not
allow for detection of IDO1. IDO1 can be localized in endothelial cells of
the villous chorion after HIER using citrate buffer at pH 6 (B). HIER with
retrieval buffer at pH 9 (C) enhanced the staining intensity and allows
for a more detailed interpretation of IDO1 immunolocalization. The
scale bar represents 100 mm.
doi:10.1371/journal.pone.0021774.g011
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demonstrated to occur as early as the 13
th week of gestation [38].
This finding parallels the fact that, although antiretroviral therapy
for preventing mother-to-child transmission of HIV is partially
effective when given only at parturition, the efficacy is greater
when given throughout pregnancy [39]. Suppression of an
allogeneic immune response will be even more important as
endothelial cells function as semi-professional antigen-presenting
cells [40].
Vascular endothelial expression of IDO1 is not restricted to the
feto-maternal interface. There are positive microvascular endo-
thelial cells in a variety of tumors [41,42] (and own unpublished
observations for hepatocellular carcinoma), leaving room for
speculation on analogies of immune suppression in the placenta
and suppression of the immune response to tumors.
A hint concerning a possible non-immunological role of
endothelial expression of IDO1 has be given by the recent report
that kynurenine metabolized by IDO which is expressed in the
endothelium of mice infected with malaria parasites or induced by
endotoxinemia contributes to arterial vessel relaxation and the
control of blood pressure [43]. We found high concentrations of
kynurenine in the serum or plasma from the umbilical cord or
from vessels of the chorionic plate. These concentrations were
much higher than in plasma samples of peripheral blood in
pregnant or non-pregnant women [44,45] or in blood from
healthy blood donors [19] and are probably due to IDO1 activity
of the endothelial cells. This suggests that endothelial IDO1
expressed in healthy placenta and decidua play a role in keeping
vessels dilated which are vital for the maintenance of the fetus who
in the course of pregnancy is increasingly dependent on maternal
blood circulation. Given the relatively high concentration of
kynurenine in the umbilical cord blood, this might provide a
systemic effect on fetal circulation. For the circulation of the
pregnant women no such systemic effect is to be expected, as the
kynurenine concentration in the peripheral blood remains low
during pregnancy [44,45]. However, uterine expression of
endothelial IDO1 may lead to local vasodilatation.
Reduced placenta IDO activity correlates with the severity of
pre-eclampsia. Pregnant mice carrying hemiallogeneic concepti
treated with an IDO inhibitor developed high blood pressure and
proteinuria in addition to local circulation impairment in the
placenta, which is analogous to the lesions that are characteristic of
human pre-eclampsia [46]. It remains to be elucidated whether
this is a direct effect based on blocking of endothelial IDO.
One might argue for a further potential role of IDO1: The
enzyme is implicated in inhiting growth of intracellular parasites
(Toxoplasma gondii, Chlamydia psittaci) as well as extracellular
bacteria [18]. IDO1 expression in endothelial cells may inhibit
extravasation of microbial pathogens from the blood into the tissue
through the depletion of tryptophan in the local tissue adjacent to
the blood stream [30]. This may contribute to protection of the
fetus against infection.
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